FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Aurobindo Pharma Valsartan Tablets 320 mg Recall

Valsartan Tablets USP 320 mg, 90 count bottles, Rx only, Distributed by: Aurobindo Pha…

Aurobindo Pharma USA Inc. · East Windsor, NJ

Risk level
Class II
Reported by FDA
Mar 27, 2019
Recall ID
D-1035-2019
Check your lot numberHow we source this data

Summary

Aurobindo Pharma recalled Valsartan Tablets 320 mg starting Dec 31, 2018. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1035-2019 on Mar 27, 2019. Reason: GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. Status: Ongoing.

Why it was recalled

GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

Product description

Valsartan Tablets USP 320 mg, 90 count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., Dayton, NJ --- NDC 65862-573-90

Lot numbers, UPCs & expiration codes

Lot Numbers: 473180004A, 473180005A, exp. date Feb 2020; 473180006A, exp. date Mar 2020; 473180016A, 473180017A, exp. date May 2020; 473170019A, exp. date Oct 2019

Where it was sold

Product was distributed to major distribution chains throughout the United States.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1035-2019
Classification
Class II
Status
Ongoing
Recall initiated
Dec 31, 2018
FDA report date
Mar 27, 2019
Quantity
N/A
Recall type
Voluntary: Firm initiated
Recalling firm
Aurobindo Pharma USA Inc.

Original FDA data

Every field from FDA enforcement report D-1035-2019, exactly as published.

Show all FDA fields
City
East Windsor
State
NJ
Status
Ongoing
Country
United States
Event ID
82114
Address
279 Princeton Hightstown Rd
Code information
Lot Numbers: 473180004A, 473180005A, exp. date Feb 2020; 473180006A, exp. date Mar 2020; 473180016A, 473180017A, exp. date May 2020; 473170019A, exp. date Oct 2019
Postal code
08520-1401
Report date
Mar 27, 2019
Product type
Drugs
Recall number
D-1035-2019
Classification
Class II
Recalling firm
Aurobindo Pharma USA Inc.
Reason for recall
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Valsartan Tablets USP 320 mg, 90 count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., Dayton, NJ --- NDC 65862-573-90
Distribution pattern
Product was distributed to major distribution chains throughout the United States.
Recall initiation date
Dec 31, 2018
Initial firm notification
Letter
Center classification date
Mar 21, 2019

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1035-2019, published Mar 27, 2019. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls